MSH6 and cancer: In estimates based on historical segregation analysis, MLH1 and MSH2 are quoted to have a lifetime incidence of any cancer of up to 80–90 per cent without risk-reducing surveillance, whereas MSH6 and PMS2 have been linked with more moderate 40–60 per cent penetrance.